Clinical stage compound for the treatment of metabolic syndrome

KD3010 is a potent, orally administered, peroxisome proliferator-activated receptor-delta (PPARδ) agonist that exhibits ~1000-fold selectivity over PPARγ and PPARα.

Data from relevant animal models demonstrate that KD3010 results in significant reduction of central adiposity, atherogenic lipid profiles, and improved glucose utilization/insulin sensitivity. Data from GLP safety pharmacology and toxicology studies have defined a favorable safety profile for entry in to the clinic.

The KD3010 IND was filed 2Q06. Phase I clinical trials have been initiated.

KD3010 Fact Sheet